Back to Journals » Lung Cancer: Targets and Therapy » Volume 12

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Total article views   HTML views PDF downloads Totals
9,932 Dovepress* 7,281+ 210 7,491
PubMed Central* 2,651 384 3,035
Totals 9,932 594 10,526
*Since 2 November 2021
Total mentioned Facebook Delicious Reddit Twitter Others
21 0 0 1 8 12

View citations on PubMed Central and Google Scholar